Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Key words Prostate cancer  (1)
  • Key words: Fluorine-18 fluorodeoxyglucose  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Indication for nuclear medicine therapy in advanced cancer of the prostate (1998)
    Springer
    Der Urologe 37 (1998), S. 162-166 
    Details
    ISSN: 1433-0563
    Keywords: Key words Prostate cancer ; Palliation ; Radionuclides ; Schlüsselwörter Prostatakarzinom ; Palliation ; Radionuklidtherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei Patienten mit fortgeschrittenem Prostatakarzinom ist die suffiziente Therapie schmerzhafter Knochenmetastasen primäres, interdisziplinäres Behandlungsziel. Vorrangig erscheint die Erhaltung der Lebensqualität, nicht die Lebensverlängerung. Neben einer oralen Schmerzmedikation und lokalen Schmerzbestrahlung bieten systemische Radionuklidtherapien hilfreiche, risikoarme nuklearmedizinische Therapiealternativen in der Palliation schmerzhafter, multilokulärer osteoplastischer Knochenmetastasen. In Abhängigkeit vom gewählten Radiopharmazeutikum werden Ansprechraten und Schmerzreduktion in 65–80 % beschrieben. Die Dauer der Schmerzlinderung liegt im Mittel bei 6–12 Wochen. Während dieser Zeit kann die nebenwirkungsreiche, morphinhaltige Schmerzmedikation deutlich reduziert und in einigen Fällen ganz abgesetzt werden, was wiederum die Lebensqualität verbessert. Nach Abklingen der geringgradigen Myelodepression kann die Radionuklidtherapie wiederholt werden. Nachteilig bleibt allein der zweitägige stationäre Aufenthalt aufgrund geltender Strahlenschutzverordnung.
    Notes: Summary For patients with advanced prostate cancer efficient therapy of painfull bony lesions is the primary goal of interdisciplinary treatment strategies. Preservation of quality of life appears to be the main aim rather than prolongation of life. Apart from oral pain relief and local irradiation systemic treatment with radionuclides offers low-risk radiotherapeutic strategies for the palliation of painful, multifocal osteoplastic bone metastases. Depending on the radiopharmaceutical substance chosen response and reduction of pain are described in 65–80 %. The duration of pain relief lasts between 6–12 weeks. During this time the morphine based medication can be reduced and in some cases withdrawn which positively effects quality of life. After improvement of myelosuppression treatment with radionuclides can be repeated. Patients have to be hospitalized for two days because of protection from radiation procedures.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s001200050167
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumours (1997)
    Springer
    European journal of nuclear medicine 24 (1997), S. 1138-1145 
    Details
    ISSN: 1619-7089
    Keywords: Key words: Fluorine-18 fluorodeoxyglucose ; Positron emission tomography ; Technetium-99m methoxyisobutylisonitrile ; Scintimammography ; Breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. The aim of this study was to compare, in breast cancer patients, the diagnostic accuracy of positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) and scintimammography (SMM) using technetium-99m methoxyisobutylisonitrile (MIBI). A total of 20 patients (40 breasts with 22 lesions) were evaluated serially with MIBI and, on the following day, with FDG. For SMM, planar and single-photon emission tomography imaging in the prone position was performed starting at 10 min following the injection of MIBI (740 MBq). For PET, scans were acquired 45–60 min after the injection of FDG (370 MBq) and attentuation correction was performed following transmission scans. Results from SMM and PET were subsequently compared with the histopathology results. True-positive results were obtained in 12/13 primary breast cancers (mean diameter=29 mm, range 8–53 mm) with both FDG and MIBI. False-negative results were obtained in two local recurrences (diameter 〈9 mm) with both FDG and MIBI. In benign disease, FDG and MIBI did not localize three fibrocystic lesions, two fibroadenomas and one inflammatory lesion (true-negative), but both localized one fibroadenoma (false-positive). Collectively, the results demonstrate a sensitivity of 92%, and a specificity of 86%, for primary breast cancer regardless of whether FDG or MIBI was used. In contrast to MIBI scintigraphy, FDG PET scored the axillae correctly as either positive (metastatic disease) or negative (no axillary disease) in all 12 patients. The tumour/non-tumour ratio for MIBI was 1.97 (range 1.43–3.1). The mean standard uptake value (SUV) for FDG uptake was 2.57 (range 0.3–6.2). The diagnostic accuracy of SMM was equivalent to that of FDG PET for the detection of primary breast cancer. For the detection of in situ lymph node metastases of the axilla, FDG seems to be more sensitive than 99mTc-MIBI.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01254246
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...